TMX Newsfile·2026-02-18 00:20Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for misrepresentation and failure to disclose critical information regarding its drug candidate for Huntington's Disease, potentially affecting investors who purchased shares during the specified period [1][5]. Group 1: Lawsuit Announcement - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of uniQure ordinary shares between September 24, 2025, and October 31, 2025 [1]. - Investors who purchased shares during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Process and Participation - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by April 13, 2026, to represent the class in the litigation [1][3]. Group 3: Details of the Case - The lawsuit alleges that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [5]. - The claims suggest that the defendants' statements regarding uniQure's business and prospects lacked a reasonable basis, leading to investor damages when the truth was revealed [5]. Group 4: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [4].